MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/js9.0000000000001891

Медицинская библиотека · International journal of surgery (London, England) · 2025

Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study.

Li Bowen, Xie Shule, Han Jingjing, Cao Haotian, Lin Zhaoyu, Hu Huijun, Pan Chaobin, Li Qunxing, Li Jintao, Wang Liansheng, Chen Suling, Rao Guangxin, Huang Guoxin, Tan Yongmei, Chen Rongxi, Fan Song, Duan Xiaohui, Li Haigang, Li Jinsong

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Surgery and postoperative adjuvant therapy is the standard treatment for locally advanced resectable oral squamous cell carcinoma (OSCC), while neoadjuvant chemoimmunotherapy (NACI) is believed to lead to better outcomes. This study aims to investigate the effectiveness of NACI regimens in treating locally advanced resectable OSCC.

MATERIALS AND

METHODS

Patients diagnosed with locally advanced resectable OSCC who received NACI and non-NACI were reviewed between December 2020 and June 2022 in our single center. The pathologic response was evaluated to the efficacy of NACI treatment. Adverse events apparently related to NACI treatment were graded by Common Terminology Criteria for Adverse Events, version 5.0. The disease-free survival (DFS) and overall survival (OS) rate were assessed.

RESULTS

Our analysis involved 104 patients who received NACI. Notably, the pathological complete response rate was 47.1%, and the major pathological response (MPR) rate was 65.4%. The top three grade 1-2 treatment-related adverse events (TRAEs) were alopecia (104; 100%), anemia (81; 77.9%), and pruritus (62; 59.6%). Importantly, patients achieving MPR exhibited higher programmed cell death-ligand 1 (PD-L1) combined positive scores (CPS). The diagnostic value of CPS as a biomarker for NACI efficacy was enhanced when combined with total cholesterol level. The 3-year estimated DFS rates were 89.0% in the NACI cohort compared to 60.8% in the non-NACI cohort, while the 3-year estimated OS rates were 91.3 versus 64.0%, respectively.

CONCLUSIONS

The NACI treatment showed safe and encouragingly efficacious for locally advanced resectable OSCC patients. The high response rates and favorable prognosis suggest this approach as a potential treatment option. Prospective randomized controlled trials are needed to further validate these findings.

Для цитирования: Li Bowen, Xie Shule, Han Jingjing, Cao Haotian, Lin Zhaoyu, Hu Huijun, Pan Chaobin, Li Qunxing, Li Jintao, Wang Liansheng, Chen Suling, Rao Guangxin, Huang Guoxin, Tan Yongmei, Chen Rongxi, Fan Song, Duan Xiaohui, Li Haigang, Li Jinsong. Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study.. International journal of surgery (London, England). 2025. DOI: 10.1097/js9.0000000000001891.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.